ALK and non-small cell lung carcinoma: The objective of our analysis was to externally validate this framework to simulate OS and more specifically alectinib vs. crizotinib treatment effect (OS HR) in patients with treatment-naive advanced ALK-positive NSCLC in the alectinib ALEX study [4].